Markers of Systemic Inflammation in Smoker and Non-Smoker Chronic Obstructive Pulmonary Diseases

Non-smoker and tobacco smoker also have different inflammatory and proteolytic effects in the lung in experimental studies. Objectives: To compare the clinical, investigational profile and inflammatory markers e.g. ESR, CRP, Fibrinogen, IL-5 and IL-6 between smoker and non-smoker COPD patients.2. To compare the CAT score, mMRC score and various spirometry parameters between smoker and non-smoker COPD patients3. To calculate the diagnostic performance, sensitivity and specificity of inflammatory markers e.g. ESR, CRP, Fibrinogen, IL-5 and IL-6 between smoker and non-smoker COPD patients. Methods: In this cross-sectional study 80 subjects between age group of 40 to 65 years participated. This study included category A, B and C patients of COPD included and category D of COPD patients were excluded and those who were exposed to occupational exposure to smoke. Serum levels of inflammatory markers including ESR, CRP, IL-5, IL-6, and Fibrinogen measured. Results: This study showed that there was statistically significant difference in ESR, CRP and fibrinogen levels between smoker and non-smoker COPD. There was also significant statistical difference between smoker and non-smoker COPD with respect to gender, old TB, haemoglobin, and the spirometry parameters. Conclusions: Therefore, this phenotypical categorization of patients with COPD may result in better understanding of the varied pathophysiology and help as screening tool for diagnosis of non-smoker COPD patients. ESR, CRP and fibrinogen may be used as a screening tool between smoker and non-smoker COPD patients, for a focused approach to treatment.